NASDAQ:EYEN Eyenovia (EYEN) Stock Price, News & Analysis $15.96 +5.40 (+51.14%) Closing price 07/2/2025Extended Trading$15.96 0.00 (0.00%) As of 07/2/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Eyenovia Stock (NASDAQ:EYEN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Eyenovia alerts:Sign Up Key Stats Today's Range$10.70▼$17.1850-Day Range$1.04▼$15.9652-Week Range$0.85▼$124.80Volume4.63 million shsAverage Volume1.26 million shsMarket Capitalization$45.96 millionP/E RatioN/ADividend YieldN/APrice Target$2.00Consensus RatingHold Company Overview Eyenovia, Inc. is a clinical‐stage ophthalmic biopharmaceutical company dedicated to developing microdose-based treatments for common eye disorders. Leveraging its proprietary Optejet® platform, the company delivers precise, low-volume doses of established and novel therapeutic agents directly to the ocular surface. This targeted approach is designed to enhance drug efficacy while minimizing side effects, positioning Eyenovia at the forefront of innovation in eye‐care delivery systems. The company’s lead programs include MicroLine®, a topical treatment for presbyopia that uses a combination of low-concentration muscarinic agonists to restore near vision, and MiDrops™, an investigational formulation aimed at slowing the progression of myopia in children. Both products employ the Optejet platform’s high-precision microdosing technology to administer doses of less than 10 microliters, enabling consistent delivery and improved patient compliance. Eyenovia continues to advance these candidates through late-stage clinical trials and regulatory interactions across key markets. Founded in 2010 and headquartered in Marlborough, Massachusetts, Eyenovia operates research and development facilities in the United States and maintains strategic partnerships to support future commercialization efforts worldwide. Under the leadership of Chief Executive Officer Anthony E. Adamis, M.D., the company has expanded its management team and board of directors to include seasoned professionals with deep expertise in ophthalmology, clinical development, and regulatory affairs. This experienced leadership group is driving Eyenovia’s mission to transform the standard of care for patients affected by visual disorders.AI Generated. May Contain Errors. Read More Eyenovia Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks20th Percentile Overall ScoreEYEN MarketRank™: Eyenovia scored higher than 20% of companies evaluated by MarketBeat, and ranked 845th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.0 / 5Analyst RatingHold Consensus RatingEyenovia has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageEyenovia has received no research coverage in the past 90 days.Read more about Eyenovia's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Eyenovia are expected to grow in the coming year, from ($41.60) to ($16.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Eyenovia is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eyenovia is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Eyenovia's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.05% of the float of Eyenovia has been sold short.Short Interest Ratio / Days to CoverEyenovia has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Eyenovia has recently decreased by 31.49%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEyenovia does not currently pay a dividend.Dividend GrowthEyenovia does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.05% of the float of Eyenovia has been sold short.Short Interest Ratio / Days to CoverEyenovia has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Eyenovia has recently decreased by 31.49%, indicating that investor sentiment is improving significantly. News and Social Media3.0 / 5News Sentiment0.40 News SentimentEyenovia has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Eyenovia this week, compared to 2 articles on an average week.Search Interest25 people have searched for EYEN on MarketBeat in the last 30 days. This is an increase of 127% compared to the previous 30 days.MarketBeat Follows1 people have added Eyenovia to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Eyenovia insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.10% of the stock of Eyenovia is held by insiders.Percentage Held by InstitutionsOnly 25.84% of the stock of Eyenovia is held by institutions.Read more about Eyenovia's insider trading history. Receive EYEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eyenovia and its competitors with MarketBeat's FREE daily newsletter. Email Address EYEN Stock News HeadlinesEyenovia (NASDAQ:EYEN) Stock Rating Upgraded by Wall Street ZenJuly 5, 2025 | americanbankingnews.comHyperion DeFi stock soars after company rebrands from EyenoviaJuly 2, 2025 | uk.investing.comTop Picks for Trump’s Pro-Crypto AmericaMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything… | Crypto 101 Media (Ad)Eyenovia COO Kern Leaves as Part of Workforce ReductionJuly 2, 2025 | marketwatch.comEyenovia, Inc. Rebrands to Hyperion DeFi, Inc. and Announces Nasdaq Trading Under “HYPD” TickerJuly 2, 2025 | quiverquant.comQEyenovia Adds $10 Million in HYPE to its Treasury Holdings in Preparation for Strategic Onchain EngagementJune 30, 2025 | finance.yahoo.comEyenovia Announces Co-Branded Validator with KinetiqJune 25, 2025 | tmcnet.comEyenovia, Inc. Acquires $50 Million in HYPE Tokens, Plans Validator Deployment and FDA Registration for Optejet UFD - NasdaqJune 25, 2025 | nasdaq.comSee More Headlines EYEN Stock Analysis - Frequently Asked Questions How have EYEN shares performed this year? Eyenovia's stock was trading at $11.68 at the start of the year. Since then, EYEN stock has increased by 36.6% and is now trading at $15.96. How were Eyenovia's earnings last quarter? Eyenovia, Inc. (NASDAQ:EYEN) released its quarterly earnings results on Monday, May, 19th. The company reported ($1.59) earnings per share for the quarter, beating analysts' consensus estimates of ($7.20) by $5.61. The firm earned $1.60 million during the quarter, compared to analysts' expectations of $1.60 million. When did Eyenovia's stock split? Eyenovia's stock reverse split on the morning of Monday, February 3rd 2025.The 1-80 reverse split was announced on Tuesday, January 28th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 31st 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. When did Eyenovia IPO? Eyenovia (EYEN) raised $30 million in an IPO on Thursday, January 25th 2018. The company issued 2,700,000 shares at a price of $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners acted as the underwriters for the IPO. How do I buy shares of Eyenovia? Shares of EYEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Eyenovia own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eyenovia investors own include Plug Power (PLUG), Advanced Micro Devices (AMD), Micron Technology (MU), OPKO Health (OPK), Pfizer (PFE), NVIDIA (NVDA) and Tesla (TSLA). Company Calendar Last Earnings5/19/2025Today7/08/2025Next Earnings (Estimated)8/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EYEN CIK1682639 Webwww.eyenoviabio.com Phone(917) 289-1117FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Price Target for Eyenovia$2.00 High Price Target$2.00 Low Price Target$2.00 Potential Upside/Downside-87.5%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($58.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$49.82 million Net Margins-62,238.41% Pretax Margin-62,238.41% Return on EquityN/A Return on Assets-316.90% Debt Debt-to-Equity RatioN/A Current Ratio0.34 Quick Ratio0.34 Sales & Book Value Annual Sales$60 thousand Price / Sales766.08 Cash FlowN/A Price / Cash FlowN/A Book Value($695.52) per share Price / Book-0.02Miscellaneous Outstanding Shares2,880,000Free Float2,678,000Market Cap$45.96 million OptionableOptionable Beta2.47 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:EYEN) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eyenovia, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eyenovia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.